Publications by authors named "M Iwaki"
Article Synopsis
- The study assessed the effectiveness of serum type 4 collagen 7S (COL4-7S) compared to the Enhanced Liver Fibrosis (ELF) score in detecting liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
- Among 1,368 patients, 794 were analyzed, revealing that both COL4-7S and ELF scores rise with increasing fibrosis, but COL4-7S showed significantly better performance for identifying advanced fibrosis (≥2) especially in diabetic patients.
- Overall, COL4-7S proved to be at least as effective as the ELF score in diagnosing advanced liver disease in MASLD patients.
Objectives: New scores were developed to identify at-risk metabolic dysfunction-associated steatohepatitis (MASH) using multiparametric MRI (mpMRI).
Materials And Methods: A prospective study was conducted on 176 patients with suspected or diagnosed metabolic dysfunction-associated steatotic liver disease (MASLD) paired with an MR scan, vibration-controlled transient elastography (VCTE), and liver biopsy. Liver stiffness measurement (LSM) using magnetic resonance elastography (MRE), proton density fat fraction (PDFF), and mpMRI-based corrected T1 (cT1) were combined to develop a one-step strategy, named MPcT (MRE + PDFF + cT1, combined score), and a two-step strategy-MRE-based LSM followed by PDFF with cT1 (M-PcT, paired score) for diagnosing at-risk MASH.
Purpose: To evaluate the impact of varying concentrations of 3 mol% yttria-stabilized tetragonal zirconia polycrystalline ceramic (3Y-TZP) nanoparticles on mechanical properties of three-dimensional (3D)-printed resins in stereolithography (SLA) technology.
Materials And Methods: A total of four groups (n = 6) of specimens were printed. Pure 3D-printed resin was used as the control group (0 wt%).
Introduction: Non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a phenotype of the metabolic syndrome in the liver and is clearly associated with metabolic abnormalities such as hyperglycaemia and dyslipidaemia. Although the prevalence of MASLD is increasing worldwide, there is currently no consensus on the efficacy and safety of the drugs used to treat MASLD/metabolic dysfunction-associated steatohepatitis (MASH). Pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, was designed to have higher peroxisome proliferator-activated receptor alfa (PPARα) agonist activity and selectivity than existing PPARα agonists, and in development trials, without increasing creatinine levels, lipid parameters and alanine aminotransferase (ALT) were significantly improved.
View Article and Find Full Text PDFBackground And Aims: Although numerous noninvasive diagnostic methods have been developed to predict liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), they lack markers for predicting lobular inflammation, hepatocellular ballooning, or changes related to metabolic dysfunction-associated steatohepatitis (MASH). We examined serum cytokeratin 18 fragment (CK18F) as a noninvasive marker for predicting treatment response and "at-risk MASH" and "MASH resolution" in patients with MASLD.
Methods: One-hundred-and-ten patients with MASLD who underwent repeated biopsy were enrolled (age, 4 [0.